Advertisement
News
Advertisement

Summary Box: Amgen CEO sees higher sales in 2012

Mon, 01/09/2012 - 11:45am
The Associated Press

RISING TIDE: Robert Bradway, on deck as Amgen's next CEO, predicts newer products and expanding operations into more countries to bring higher revenue down the road.

MOMENTUM: Positive developments include last year's purchase of a cancer vaccine developer and moves to protect long-term sales of top seller Enbrel, for psoriasis and rheumatoid arthritis, and anemia treatment Epogen.

MANAGEMENT MOVES: Along with Bradway, Amgen has appointed new heads of commercial operations and research and development. It also plans more share buybacks.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading